Positive opinion for Novo Nordisk’s Sogroya
Therapy has been developed for use among children and adolescents with growth hormone deficiency
Read More
Tag: Sogroya
Novo Nordisk’s Sogroya moves closer towards EU approval
CHMP recommended marketing authorisation for human growth hormone therapy
Read More
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
- Incyte treatment for advanced anal cancer approved in Europe
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
